orantinib has been researched along with Necrosis in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arioka, H; Ikeda, M; Kanai, F; Kawabe, T; Kondo, Y; Morizane, C; Obi, S; Okusaka, T; Omata, M; Sato, S; Shiina, S; Tagawa, K; Taniguchi, M; Tateishi, R; Yoshida, H | 1 |
1 trial(s) available for orantinib and Necrosis
Article | Year |
---|---|
A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Area Under Curve; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Necrosis; Oxindoles; Propionates; Pyrroles; Survival Analysis; Treatment Outcome; Vascular Cell Adhesion Molecule-1 | 2011 |